 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Keytruda (pembrolizumab) / Merck (MSD)
P1 data, Journal, Combination therapy, Monotherapy, PD(L)-1 Biomarker: Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies. (Pubmed Central) - Oct 26, 2022
P1, P1/2
Patients treated with MK-4621 monotherapy or in combination with pembrolizumab experienced tolerable safety and modest antitumor activity, and there was evidence that MK-4621 activated the RIG-I pathway. At the doses tested, MK-4621 did not confer meaningful clinical benefit.
- ||| Keytruda (pembrolizumab) / Merck (MSD), MK 4621 / Merck (MSD)
Trial termination, Monotherapy, Metastases: Intratumoral/Intralesional Administration of MK-4621/JetPEI (clinicaltrials.gov) - Aug 31, 2021
P1, N=30, Terminated, Sponsor: Merck Sharp & Dohme Corp.
At the doses tested, MK-4621 did not confer meaningful clinical benefit. Completed --> Terminated; Business Reasons
- || Keytruda (pembrolizumab) / Merck (MSD), MK 4621 / Merck (MSD)
Trial completion, Enrollment change, Monotherapy, Metastases: Intratumoral/Intralesional Administration of MK-4621/JetPEI (clinicaltrials.gov) - Mar 11, 2021
P1, N=30, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated; Business Reasons Active, not recruiting --> Completed | N=72 --> 30
- ||| MK 4621 / Merck (MSD)
$MRK Rig1 agonist MK-4621 #SITC20 (Twitter) - Nov 13, 2020
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_2103;
P1, P1/2
Conclusions The combination of intratumoral MK-4621 plus intravenous pembrolizumab had a manageable safety profile. At the highest dose level, modest antitumor activity was observed in patients treated with combination therapy.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_1957;
P1, P1/2
Conclusions The combination of intratumoral MK-4621 plus intravenous pembrolizumab had a manageable safety profile. At the highest dose level, modest antitumor activity was observed in patients treated with combination therapy.
- | Keytruda (pembrolizumab) / Merck (MSD), MK 4621 / Merck (MSD)
Enrollment closed, Monotherapy, Metastases: Intratumoral/Intralesional Administration of MK-4621/JetPEI (clinicaltrials.gov) - Apr 8, 2020
P1, N=72, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
At the highest dose level, modest antitumor activity was observed in patients treated with combination therapy. Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), MK 4621 / Merck (MSD)
Trial primary completion date, Monotherapy, Metastases: Intratumoral/Intralesional Administration of MK-4621/JetPEI (clinicaltrials.gov) - Feb 28, 2019
P1, N=72, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2021 --> Apr 2021
- | Keytruda (pembrolizumab) / Merck (MSD), MK 4621 / Merck (MSD)
Enrollment open, Monotherapy, Metastases: Intratumoral/Intralesional Administration of MK-4621/JetPEI (clinicaltrials.gov) - Jan 11, 2019
P1, N=72, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jan 2021 --> Apr 2021 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), MK 4621 / Merck (MSD)
New P1 trial, Monotherapy, Metastases: Intratumoral/Intralesional Administration of MK-4621/JetPEI (clinicaltrials.gov) - Nov 12, 2018
P1, N=72, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | MK 4621 / Merck (MSD)
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) (clinicaltrials.gov) - Jul 27, 2018
P1/2, N=15, Terminated, Sponsor: Rigontec GMBH
Not yet recruiting --> Recruiting N=54 --> 15 | Trial completion date: Dec 2019 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> May 2018; Group B not started for business reasons.
- || MK 4621 / Merck (MSD)
Enrollment closed, Metastases: Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) (clinicaltrials.gov) - May 3, 2018
P1/2, N=54, Active, not recruiting, Sponsor: Rigontec GMBH
N=54 --> 15 | Trial completion date: Dec 2019 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> May 2018; Group B not started for business reasons. Recruiting --> Active, not recruiting
- || MK 4621 / Merck (MSD)
Trial primary completion date, Metastases: Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) (clinicaltrials.gov) - Apr 12, 2017
P1/2, N=54, Recruiting, Sponsor: Rigontec GMBH
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2018 --> Dec 2019
- | MK 4621 / Merck (MSD)
New P1/2 trial, Metastases: Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) (clinicaltrials.gov) - Feb 27, 2017
P1/2, N=54, Recruiting, Sponsor: Rigontec GMBH